Please ensure Javascript is enabled for purposes of website accessibility

Why Noble Energy, Voyager Therapeutics, and NXP Semiconductors Jumped Today

By Dan Caplinger - Feb 20, 2018 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out which of these stocks made a sweet deal.

Tuesday saw the broader market turn lower late in the session on weakness in the Dow Jones Industrials. Bad news at the top of the brick-and-mortar retail sector hurt consumer goods stocks, and more generally, investors seemed uncertain whether major benchmarks were ready to return to all-time highs or would have to suffer another corrective phase. Despite the swirl of volatility, some stocks posted solid gains. Noble Energy (NBL), Voyager Therapeutics (VYGR), and NXP Semiconductors (NXPI) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Noble Energy gets a lift

Shares of Noble Energy rose 11% after the oil and natural gas production company reported its latest financial results and announced a major supply deal. Revenue was up nearly 20% due to record quarterly volumes from onshore oil assets in the U.S., especially Texas, and the company reversed a loss in the year-earlier period with a solid profit for the quarter. Noble Energy also said that it had signed contracts to supply natural gas from Israeli gas fields to buyers in Egypt, with initial delivery quantities of roughly 350 million cubic feet from each of two separate fields. With Israel's Delek also involved in the $15 billion deal, the agreement points to thawing relations in the Middle East that could support Noble Energy's business there.

Well in grass field on clear day with worker wearing hard hat walking toward it.

Image source: Noble Energy.

Voyager partners up

Voyager Therapeutics stock soared 22% in the wake of the company's announcement of a collaboration with industry giant AbbVie (ABBV) in the fight against Alzheimer's and similar diseases. Under the strategic deal, AbbVie will pay Voyager an up-front payment of $69 million, with the potential to pay as much as $155 million in preclinical and phase 1 option payments. Development and regulatory milestone payments could add another $895 million to the total, not including tiered royalties on commercial sales globally of treatments resulting from the program for Alzheimer's and other tau-related neurodegenerative diseases. Voyager has gotten positive attention before, but the latest deal validates its approach and points to potentially game-changing developments in the future.

NXP lands a better deal

Finally, shares of NXP Semiconductors gained 6%. The semiconductor chipmaker received a larger buyout bid from Qualcomm (QCOM), which boosted its cash offer from $110 to $127.50 per share. The sweetened terms enticed major NXP shareholders, including activist investors at Elliott Management, to support the merger. The relatively small share-price gain reflects the fact that NXP investors already expected a higher bid, but for Qualcomm, the deal serves the dual purpose of both closing on a valuable asset in NXP and fending off a hostile takeover bid from Broadcom.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NXP Semiconductors N.V. Stock Quote
NXP Semiconductors N.V.
NXPI
Noble Energy, Inc. Stock Quote
Noble Energy, Inc.
NBL
Voyager Therapeutics Stock Quote
Voyager Therapeutics
VYGR
QUALCOMM Incorporated Stock Quote
QUALCOMM Incorporated
QCOM
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.